Stocks
Oramed Pharmaceuticals Inc.ORMP
NASDAQHealthcareBiotechnology$3.43+1.48%
Price as of · delayed, not real-time
Focused on oral delivery solutions for pharmaceuticals, this biopharma company develops proprietary technologies to replace injectable treatments. Investors track its lead candidate, an oral insulin capsule currently in Phase 3 trials for type 2 diabetes, which could disrupt the $22B insulin market if approved.
Market Cap: $136.7M52W Range: $1.82 – $3.76
Congressional Interest in Oramed Pharmaceuticals Inc. (ORMP)
2 members of Congress have disclosed 4 trades in Oramed Pharmaceuticals Inc. (ORMP), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
2
Buys
1
Sells
3
Who in Congress Is Trading ORMP?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-01-10 | Brad Knott | sell | $15K – $50K |
| 2022-01-14 | Andrew Garbarino | sell | $1K – $15K |
| 2021-10-01 | Andrew Garbarino | sell | $1K – $15K |
| 2021-04-23 | Andrew Garbarino | buy | $1K – $15K |